衣藻质体分裂相关基因CrFtsZ2的克隆及其进化分析

ＦｔｓＺ(ｆｉｌａｍｅｎｔｉｎｇｔｅｍｐｅｒａｔｕｒｅｓｅｎｓｉｔｉｖｅ)是一类从大肠杆菌温度敏感型突变体中分离到的基因 .该基因与Ｅ .ｃｏｌｉ细胞分裂密切相关 .突变体由于细胞分裂受阻而呈现“长丝状”[1] .此类基因于 1980年首次被克隆[2 ] .随后的研究表明 ,ＦｔｓＺ蛋白在Ｅ .ｃｏｌｉ分裂细胞的凹陷处形成环状多聚体 ,Ｚ环 ,是Ｅ .ｃｏｌｉ细胞分裂的限制因子[3 ] .衣藻属于绿藻 ,在现存的所有单细胞真核藻类中 ,绿藻是与陆生植物亲缘关系最近的一支[4] .由于衣藻为单细胞真核生物 ,并且仅含有一个巨大的叶绿体 ,因而是研究…     

Caveolin-1基因沉默促进乳腺上皮细胞ERα36 介导的PI3K/AKT信号通路的激活

Caveolin-1(窖蛋白-1)单倍不足可以促进正常乳腺细胞的早期转化, 与新型雌激素受体亚型ERα36介导的膜始动雌激素信号通路的激活有关, 但是关于其机制并未被研究清楚. 本文利用siRNA技术建立了Caveolin-1低表达而ERα36高表达的稳定传代细胞模型MCF10ACE, 采用基因芯片技术检测了ERα36高表达时雌激素信号通路基因表达谱, 研究了ERα36在雌激素激活的PI3K/AKT信号通路中的作用及其与乳腺细胞转化的关系. 结果表明: (1) Caveolin-1表达降低时可以以雌激素依赖性方式促进ERα36表达增加; (2) ERα36高表达可介导MCF10ACE细胞雌激素抗凋亡信号通路(PI3K/AKT)的激活, 促进其与增殖信号通路MEK/ERK之间的交叉对话, 从而使人乳腺细胞增殖加快, 逐渐转化. 结果提示, Caveolin-1与ERα36相互作用调节膜起始的雌激素信号通路是控制乳腺细胞转化的重要机制.     

A Binding Domain on Mesothelin for CA125/MUC16

Ovarian cancer and malignant mesothelioma frequently express both mesothelin and CA125 (also known as MUC16) at high levels on the cell surface. The interaction between mesothelin and CA125 may facilitate the implantation and peritoneal spread of tumors by cell adhesion, whereas the detailed nature of this interaction is still unknown. Here, we used truncated mutagenesis and alanine replacement techniques to identify a binding site on mesothelin for CA125. We examined the molecular interaction by Western blot overlay assays and further quantitatively analyzed by enzyme-linked immunosorbent assay. We also evaluated the binding on cancer cells by flow cytometry. We identified the region (296–359) consisting of 64 amino acids at the N-terminal of cell surface mesothelin as the minimum fragment for complete binding activity to CA125. We found that substitution of tyrosine 318 with an alanine abolished CA125 binding. Replacement of tryptophan 321 and glutamic acid 324 with alanine could partially decrease binding to CA125, whereas mutation of histidine 354 had no effect. These results indicate that a conformation-sensitive structure of the region (296–359) is required and sufficient for the binding of mesothelin to CA125. In addition, we have shown that a single chain monoclonal antibody (SS1) recognizes this CA125-binding domain and blocks the mesothelin-CA125 interaction on cancer cells. The identified CA125-binding domain significantly inhibits cancer cell adhesion and merits evaluation as a new therapeutic agent for preventing or treating peritoneal malignant tumors.Ovarian cancer largely is confined to the peritoneal cavity for much of its natural history (1). Peritoneal mesothelioma is a highly invasive tumor originating from the mesothelial linings of the peritoneum (2). The development of effective drug regimens against ovarian cancer and mesothelioma has proven extremely difficult.Mesothelin was first identified in 1992 by the monoclonal antibody (mAb)² K1 that was generated by the immunization of mice with human ovarian carcinoma (OVCAR-3) cells (3). The mesothelin gene encodes a 71-kDa precursor protein that is processed to a 40-kDa protein termed mesothelin, which is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein present on the cell surface (4). Mesothelin is a differentiation antigen that is present on a restricted set of normal adult tissues such as the mesothelium. In contrast, it is overexpressed in a variety of cancers including mesothelioma, ovarian cancer, and pancreatic cancer (5). In addition, mesothelin is also expressed on the surface of non-small cell lung cancer cells (6, 7), especially most lung adenocarcinomas (8).We and others have shown that mesothelin is shed from tumor cells (9, 10), and antibodies specific for mesothelin are elevated in the sera of patients with mesothelioma and ovarian cancer (11). Shed serum mesothelin has been approved by the United States Food and Drug Administration (FDA) as a new diagnostic biomarker in mesothelioma. In a Phase I clinical study of an intrapleural interferon-β gene transfer using an adenoviral vector in patients with mesotheliomas, we found that antitumor immune responses targeting mesothelin were elicited in several patients (12). A recent study indicated that anti-mesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian cancer patients (13). Pastan and colleagues (14) developed an immunotoxin (SS1P) with a Fv for mesothelin. Two Phase I clinical trials were completed at the National Cancer Institute (National Institutes of Health, Bethesda, MD) and there was sufficient antitumor activity of SS1P to justify a Phase II trial. A chimeric antibody containing the mouse SS1 Fv for mesothelin was also developed and is currently examined in a Phase I clinical trial for ovarian cancer, mesothelioma, pancreatic cancer, and non-small cell lung cancer (15).Mucins are heavily glycosylated proteins found in the mucus layer or at the cell surface of many epitheliums (16). There are two structurally distinct families of mucins, secreted and membrane-bound forms. CA125 (also known as MUC16) was first identified in 1981 by OC125, a mAb that had been developed from mice immunized with human ovarian cancer cells (17). The first cDNA clones were reported in 2001 (18, 19). CA125 is a very large membrane-bound cell surface mucin, with an average molecular mass between 2.5 and 5 million daltons. It is also heavily glycosylated with both O-linked and N-linked oligosaccharides (20). The peptide backbone of CA125 is composed of the N-terminal region, extensive Ser/Thr/Pro-rich tandem repeats (TR) with 156 amino acids each with both N- and O-glycosylations, a SEA domain with high levels of O-glycosylation and a C-terminal region with a short cytoplasmic tail (19). The SEA domain was first identified as a module commonly found in sea urchin sperm protein, enterokinase and agrin (21, 22). The significance of the SEA domain in CA125 is not clear.CA125 was originally used as a biomarker in ovarian cancer due to its high expression in ovarian carcinomas and that it is shed into the serum (23). A majority (88%) of mesotheliomas are also CA125 positive on the cell membrane (24). It was shown that 25% of peritoneal mesotheliomas have high CA125 expression (25). The intensity of CA125 membranous expression is indistinguishable between ovarian carcinomas and peritoneal mesotheliomas. Gene expression analysis using the SAGE tag data base has shown that mesothelioma has the second highest co-expression of CA125 and mesothelin after ovarian cancer (26). Rump and colleagues (26) have shown that mesothelin binds to CA125 and that this interaction may mediate cell adhesion. Scholler et al. (27) recently showed that CA125/mesothelin-dependent cell attachment could be blocked with anti-CA125 antibodies. Because mesothelin is present on peritoneal mesothelium, there may be an important role for the mesothelin-CA125 interaction in the tumorigenesis of ovarian cancer and mesothelioma in the peritoneal cavity. The mesothelin binding site on CA125 may lie within the 156-amino acid TR units, indicating multimeric binding of mesothelin to CA125. It has been found that the extraordinarily abundant N-glycans on CA125, presumably in the TR region, are required for binding to both glycosylated and non-glycosylated mesothelin (28).Here, we identified the binding site of CA125 on mesothelin by use of truncated mutagenesis and alanine replacement approaches. We measured binding qualitatively by Western blot overlay assays and quantitatively by enzyme-linked immunosorbent assay (ELISA). We also evaluated the interaction of CA125 and mesothelin on cancer cells by flow cytometry. Furthermore, we have shown that a single chain mAb (SS1) recognized the CA125-binding domain and blocked the mesothelin-CA125 interaction on cancer cells. The identified CA125-binding domain-Fc fusion protein also significantly inhibited cancer cell adhesion. Our results suggest that conformation-sensitive structures of the region (296–359) are required and sufficient for specific binding of mesothelin to CA125. The domain proteins or the antibodies that block the mesothelin-CA125 interaction merit evaluation as new therapeutic agents in treating peritoneal malignant tumors.     

中药复方连黄对小鼠T淋巴细胞亚群CD4~+、CD8~+的影响

目的探讨中药复方连黄对小鼠T淋巴细胞亚群CD4+、CD8+的影响.方法 T淋巴细胞亚群测定采用单克降抗体直接免疫荧光技术,通过流式细胞仪测定.结果经统计学分析,与对照组比较,中药复方连黄能不同程度地使CD4+、CD4+/CD8+升高,而使CD8+下降.结果表明,中药复方连黄对细胞免疫功能具有调节作用.     

黄泥螺提取物对小鼠黑色素瘤细胞B16生长的影响

为研究黄泥螺提取物对小鼠黑色素瘤细胞B16生长的影响,以及初步研究其作用机制,采用磺酰罗丹明B(SRB)法测黄泥螺提取物对B16细胞的生长抑制作用,得到48 h后半数抑制浓度(IC50)为68.56 ug/ml.当黄泥螺提取物浓度为70ug/ml时,台盼蓝排斥试验显示有部分细胞死亡.经Hoechest 33258染色并用荧光显微镜观察,发现培养的细胞中出现凋亡小体,细胞核发生固缩;DNA琼脂糖凝胶电泳呈现出DNA大片段;用流式细胞仪进一步检测表明,细胞生长周期发生变化并检测到凋亡峰.结果表明,体外培养的B16细胞经过黄泥螺提取物处理后,B16细胞增殖受到抑制,细胞周期被阻滞,B16细胞受到诱导后存在凋亡.因此,黄泥螺提取物对小鼠黑色素瘤细胞B16生长有明显的影响.     

MKP1基因对小鼠造血干细胞功能的影响

目的通过构建MKP1转基因小鼠模型,研究MKP1基因对造血干细胞自我更新能力的影响。方法运用显微注射法建立MKP1转基因小鼠;PCR和RT-PCR检测MKP1基因在转基因小鼠的表达水平;流式细胞术测定小鼠骨髓干细胞和外周血单个核细胞的比例;通过竞争性骨髓移植实验检测MKP1转基因小鼠骨髓干细胞的功能。结果建立了MKP1转基因小鼠;MKP1转基因小鼠骨髓干细胞数量减少;竞争性骨髓移植实验显示MKP1转基因骨髓干细胞来源的外周血细胞总数、B细胞、粒细胞显著减少（P〈0.001）,提示MKP1转基因小鼠骨髓干细胞的功能下降。结论在MKP1转基因小鼠模型中,MKP1基因的过表达影响了小鼠的骨髓干细胞的功能。     

糖皮质激素非基因组效应的研究

在过去的几十年间,人们认为糖皮质激素（glucocorticoid,GC）仅仅是通过改变基因的表达来发挥其生理作用,这个过程需要几个小时来完成。然而,近年来越来越多的证据表明GC对激素分泌、神经元兴奋性、机体行为及细胞形态、糖类代谢等具备快速效应,这些过程往往在数秒钟或者分种内完成,这种作用机制被称为GC的非基因组作用机制。GC的非基因组作用主要可能通过两种不同的机制起作用：（1）通过细胞膜上或者细胞质内结构未知的糖皮质激素受体（glucocorticoid Recptor,GR）来发挥非基因组作用,即为特异性非基因组效应,（2）GC主要通过改变细胞膜理化作用来发挥效应。也称为非特异性非基因组效应（non-specific nongenomic effects,NSNE）。本文通过阐述近年来GC的非基因组的作用的最新研究进展并且讨论了这些非基因组作用临床治疗过程中的联系。对糖皮质激素基因组和非基因组作用机制的深入了解有助于指导我们在临床合理用药并减少其副作用。     

胶体金免疫层析法检测猪链球菌2型的研究

目的:制备胶体金免疫层析试纸检测猪链球菌2型.方法:用柠檬酸盐还原法制备胶体金颗粒,标记猪链球菌2型多克隆抗体,通过免疫层析作用对猪链球菌2型进行检测,并对试纸条的敏感性、特异性、稳定性进行评价.结果:每毫升胶体金最佳抗体标记量为22μg/mL,最佳包被抗体浓度为2 mg/mL,最佳BSA封闭浓度为1.5%,建立的胶体金免疫层析试纸条栓出猪链球菌2型的下限为106 CFU/mL,从检测到结果判断时间为5～15 min,与其他常见致病菌及链球菌属中15个群无交叉反应.结论:获得了检测猪链球菌2型的胶体金免疫层析试纸,该法操作简便,灵敏度高,特异性强,可用于猪链球菌的快速初筛和检测.     

胶体金免疫层析快速诊断技术

免疫胶体金技术是一种新的免疫学方法,该技术是一种将胶体金颗粒与包括抗原、抗体在内的许多蛋白质标记形成免疫金复合物的技术.目前在生物医学各领域得到了日益广泛的应用.在过去的十年里,基于膜上的快速诊断技术的发展为金标免疫试剂创造了巨大的市场.使用免疫金标技术制备的标记物作为检测系统中的指示试剂,应用在检测传染病、环境污染物、毒品、早孕以及兽医等领域.这两种技术的应用很大程度上提高了体外诊断技术的简便性和快速性.本文对其基本原理及其中应注意的问题做了一些介绍,并对其应用领域及发展方向进行了探讨.     

Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis

Targeted therapies that neutralize tumour necrosis factor are often able to control the signs and symptoms of spondyloarthritis. However, recent animal model data and clinical observations indicate that control of inflammation may not be sufficient to impede disease progression toward ankylosis in these patients. Bone morphogenetic proteins and WNTs (wingless-type like) are likely to play an important role in ankylosis and could be therapeutic targets. The relationship between inflammation and new bone formation is still unclear. This review summarizes progress made in our understanding of ankylosis and offers an alternative view of the relationship between inflammation and ankylosis.